Scoring of treatment-related late effects in prostate cancer.

BACKGROUND AND PURPOSE To assess the correlation between different general and organ specific quality of life and morbidity scoring methods in a cohort of men treated with radical radiotherapy for prostate cancer. MATERIALS AND METHODS Men who had been treated with radical radiotherapy (50 Gy in 16 fractions over 21 days) for localized prostate cancer more than 3 years previously and who had no evidence of recurrent disease were invited to take part in the study. A total of 101 of 135 invited patients agreed and completed LENT/SOMA, UCLA Prostate Cancer Index, and 36 item RAND Health survey questionnaires. RESULTS The patients had comparable results with other published series with respect to the UCLA and SF-36 indices. There was significant correlation between the corresponding parts of the UCLA and LENT/SOMA scales (P<0.0005). However, for the same symptoms, a patient tended to score lower (worse) on the UCLA scale in comparison to LENT/SOMA. The relationship between the average LENT/SOMA score and maximum score was also not straightforward with each set of data revealing different information. CONCLUSIONS The LENT/SOMA questions were, in the main, more wide-ranging and informative than the UCLA index. It is helpful to give both the overall and maximum LENT/SOMA scores to most efficiently use all of the data. There may need to be a further LENT/SOMA question to allow both symptoms of tenesmus and faecal urgency to be fully addressed.

[1]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[2]  D Gillatt,et al.  Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom , 1999, BMJ.

[3]  R H Brook,et al.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. , 1998, Medical care.

[4]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[5]  D J Brenner,et al.  Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.

[6]  H. D. de Koning,et al.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Hanlon,et al.  Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. , 1997, International journal of radiation oncology, biology, physics.

[8]  W. Catalona,et al.  Quality‐of‐life outcomes for men with prostate carcinoma detected by screening , 2000, Cancer.

[9]  R. Cowan,et al.  Short report: a morbidity scoring system for Clinical Oncology practice: questionnaires produced from the LENT SOMA scoring system. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  Rick Chappell,et al.  Is α/β for prostate tumors really low? , 2001 .

[11]  P. Johnstone,et al.  Quality of life in T1-3N0 prostate cancer patients treated with radiation therapy with minimum 10-year follow-up. , 2000, International journal of radiation oncology, biology, physics.

[12]  Jacques Bernier,et al.  Late effects toxicity scoring: the SOMA scale , 1995 .

[13]  Icru Prescribing, recording, and reporting photon beam therapy , 1993 .

[14]  C. I. Franklin,et al.  Late effects of radiation therapy for prostate carcinoma: the patient's perspective of bladder, bowel and sexual morbidity. , 1998, Australasian radiology.

[15]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[16]  L. Gras,et al.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.

[17]  Lloyd,et al.  Changing trends in prostatic cancer , 1999, BJU international.

[18]  H. Bartelink,et al.  Correction for the use of the SOMA LENT tables. , 1996, International journal of radiation oncology, biology, physics.